Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. (14th March 2020)

• Record Type: Journal Article
• Authors: Matsumoto, Hiroaki; Shiraishi, Koji; Azuma, Haruhito; Inoue, Keiji; Uemura, Hirotsugu; Eto, Masatoshi; Ohyama, Chikara; Ogawa, Osamu; Kikuchi, Eiji; Kitamura, Hiroshi; Shinohara, Nobuo; Takahashi, Satoru; Tsuzuki, Toyonori; Nakagawa, Masayuki; Narumi, Yoshifumi; Nishiyama, Hiroyuki; Habuchi, Tomonori; Hinotsu, Shiro; Fujii, Yasuhisa; Fujimoto, Kiyohide; Fujimoto, Hiroyuki; Mizowaki, Takashi; Matsuyama, Hideyasu
• Other Names: Sekita Nobuyuki investigator.; Juri Hiroshi investigator.; Inada Yuki investigator.; Abe Takashige investigator.; Fukuhara Hideo investigator.; Naya Yukio investigator.; Mutoh Satoshi investigator.; Kitano Shigehisa investigator.; Kobayashi Takashi investigator.; Inamoto Teruo investigator.; Miyake Makito investigator.; Inokuchi Junichi investigator.; Hayashi Tetsutaro investigator.; Kojima Takahiro investigator.; Hashine Katsuyoshi investigator.; Kijima Toshiki investigator.; Matsui Yoshiyuki investigator.; Hara Tomohiko investigator.; Hatakeyama Shingo investigator.; Yamamoto Yoshiaki investigator.; Narita Shintaro investigator.; Tsushima Tomoyasu investigator.; Miura Takafumi investigator.; Shiroiwa Takeru investigator.; Oya Mototsugu investigator.; Gotoh Momokazu investigator.; Kume Haruki investigator.; Nasu Yasutomo investigator.; Tsunemune Katsuyuki investigator.
• Is Part Of: International journal of urology. Volume 27:Number 5(2020)
• Page Start: 362
• Page End: 368
• Publication Date: 2020-03-14
• Subjects: bladder cancer -- clinical practice guidelines -- evidence‐based medicine -- Japanese Urological Association -- position statement; Urology -- Periodicals; Genitourinary organs -- Periodicals; Urologic Diseases -- Periodicals; 616.6005
• DOI: 10.1111/iju.14210
• Languages: English
• ISSNs: 0919-8172

Abstract

Abstract: The Clinical Practice Guidelines for Bladder Cancer edited by the Japanese Urological Association were first published in 2009 and a revised edition was released in 2015. Four years has passed since the 2015 edition, and the clinical practice environment surrounding bladder cancer has drastically changed during that time. The main changes include: (i) insurance coverage of a new diagnostic method for non‐muscle‐invasive bladder cancer; (ii) insurance coverage of an immune checkpoint inhibitor in advanced and metastatic bladder cancer; and (iii) advances in robot‐assisted radical cystectomy as a minimally invasive treatment for muscle‐invasive bladder cancer. A paradigm shift in bladder cancer diagnosis and treatment is occurring day by day. Therefore, in this 2019 edition, while dealing with the above changes, we carefully selected clinical questions with clear evidence and included other clinically important points in the general statement. We also added a new chapter on rare cancers of the urinary tract. As a new method for the evaluation of study evidence level, we introduce "The Grading of Recommendations Assessment, Development and Evaluation" system modified to Japanese by the Medical Information Network Distribution Service.